Cargando…

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

BACKGROUND: Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smeijer, J. David, Kohan, Donald E., Rossing, Peter, Correa-Rotter, Ricardo, Liew, Adrian, Tang, Sydney C.W., de Zeeuw, Dick, Gansevoort, Ron T., Ju, Wenjun, Lambers Heerspink, Hiddo J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505320/ https://www.ncbi.nlm.nih.gov/pubmed/37716952 http://dx.doi.org/10.1186/s12933-023-01964-8

Ejemplares similares

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease
por: Smeijer, J. David, et al.
Publicado: (2022)

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Webb, David J., et al.
Publicado: (2017)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models
por: van den Brand, Jan A. J. G., et al.
Publicado: (2019)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
por: Groenewegen, G, et al.
Publicado: (2012)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner
por: Samad, Mohammed A., et al.
Publicado: (2015)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Improving clinical trial efficiency by biomarker-guided patient selection
por: Boessen, Ruud, et al.
Publicado: (2014)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study
por: Meems, Laura M. G., et al.
Publicado: (2016)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Preventive Role of Endothelin Antagonist on Kidney Ischemia: Reperfusion Injury in Male and Female Rats
por: Afyouni, Nazgol Esmalian, et al.
Publicado: (2015)

Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data
por: Belur Nagaraj, Sunil, et al.
Publicado: (2020)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bfgc0v9fujqtrq983klf867cef